SynthesisDermatology and therapy2026
Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis.
Synthesis in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDermatologic toxicities represent a broad and heterogeneous group of immune-related adverse events (irAEs) in patients with melanoma treated with immunotherapy, ranging from mild, transient, and self-limiting reactions to severe and potentially life-threatening conditions. Certain dermatologic toxicities have been shown to reflect immune system activation and may influence decisions on treatment continuation. The objective of this study was to comprehensively analyse real-world evidence in order to characterise the frequency, time to onset, and spectrum of dermatologic toxicities in patients with melanoma treated with immunotherapy. MATERIALS AND
methodsA systematic literature search was conducted in the PubMed and EBSCO (MEDLINE Complete) databases to identify relevant reports published between January 2014 and December 2024. Case reports and letters describing skin toxicities in adult patients with melanoma undergoing immunotherapy were included.
resultsA total of 18 patients with melanoma who had experienced dermatologic immune-related adverse events (d-irAEs) were identified. Breslow thickness ranged from 0.85 to 5.1 mm. The most frequently administered treatment was anti-PD-1 monotherapy. All reported cases involved metastatic disease (18/18, 100%; 95% CI 81.47-100%). Autoimmune bullous disorders were the most common toxicities (27.8%; 95% CI 9.69-53.48%). The median time to onset was 14 weeks (IQR 23.5 weeks; Q1 3.75 weeks; Q3 27.3 weeks). Disease progression or patient death occurred in 12 of 18 cases (66.7%; 95% CI 40.99-86.66%).
conclusionThe increasing prevalence of immunotherapy is accompanied by a paucity of real-world data, particularly with regard to mild-to-moderate skin toxicities. This underreporting emphasises the necessity for systematic documentation to more accurately define the true clinical burden of these events and to provide more personalised management strategies for patients with melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.